Agencies extend shelf life for two COVID-19 monoclonal antibody therapies 

Advertisements

Agencies extend shelf life for two COVID-19 monoclonal antibody therapies 
kpage_drupal
Jun 29, 2022

The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response and Food and Drug Administration this week extended the shelf life for certain refrigerated lots of the COVID-19 combination monoclonal antibody therapies REGEN-COV and Evusheld. They extended the shelf life for REGEN-COV from 24 months to 30 months and the shelf life for Evusheld from 18 months to 24 months. FDA last year authorized the therapies for emergency use to prevent COVID-19 in certain adults and children. REGEN-COV is not currently authorized in any U.S. region because it is unlikely to be effective against the omicron variant and subvariants.
 

Headline
Advertisements
Shopping Cart
Generated by Feedzy
error: Content is protected !!
Share via
Copy link
Powered by Social Snap